Skip to content

Author

Haiyang Yu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Efficacy and safety of osimertinib combined with anlotinib in EGFR-mutant non-squamous non-small cell lung cancer with gradual progression after first-line osimertinib therapy: a single-center retrospective cohort study

In this retrospective cohort focusing on the specific pattern of gradual progression following first-line osimertinib therapy, continued osimertinib combined with anlotinib demonstrated encouraging antitumor activity, which warrants further evaluation in prospective comparative studies.

Li-Heng Hao, Hai-Yang Yu, Yong Wang et al. · 0 citations
Aug 2026

Targeting EP2 overcomes osimertinib-tolerant persisters through metabolic and inflammatory reprogramming in non-small cell lung cancer.

Clinically, high expression levels of EP2, phosphorylated GYS1, and HIF-1α in tumor tissues correlated with poor therapeutic response to osimertinib, and elevated serum concentrations of inflammatory cytokines in NSCLC patients, suggesting that EP2 serves as a critical regulator linking metabolic reprogramming and infl...

Hai-Yang Yu, Ling Lu, Xue Hu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.